Bibliographic Details
| Title: |
Efficacy and Safety Evaluation of Different Lebrikizumab Dosages in Atopic Dermatitis Patients Over 16 to 24 Weeks: A BIOREP Registry Analysis. |
| Authors: |
Rob, Filip1 (AUTHOR) filip.rob@bulovka.cz, Kojanová, Martina2 (AUTHOR), Hercogová, Jana Třešnák3 (AUTHOR), Baláž, Monika4,5 (AUTHOR), Horažďovský, Jiří6 (AUTHOR), Vantuchová, Yvetta7 (AUTHOR), Jandová, Marie8 (AUTHOR), Hrazdírová, Kateřina9 (AUTHOR), Nečas, Miroslav10 (AUTHOR), Stuchlík, David11 (AUTHOR), Říčař, Jan12 (AUTHOR), Antal, Zdeněk13 (AUTHOR), Gkalpakiotis, Spyridon14 (AUTHOR) |
| Source: |
International Journal of Dermatology. May2026, Vol. 65 Issue 5, p1061-1063. 3p. |
| Subject Terms: |
*Drug dosage, *Safety, *Atopic dermatitis, *Treatment effectiveness, *Medical registries, *Medical research, *Interleukin-13 |
| Abstract: |
This article focuses on the evaluation of lebrikizumab, a novel anti-interleukin-13 antibody, for the treatment of moderate-to-severe atopic dermatitis (AD) with flexible dosing regimens. Using data from the Czech BIOREP registry, the study assessed the efficacy and safety of continuing lebrikizumab every 2 weeks (Q2W) versus every 4 weeks (Q4W) between Weeks 16 and 24 in patients with inadequate disease control at Week 16. Results indicated that continued Q2W dosing improved skin lesions, pruritus, and quality of life in patients not achieving sufficient response by Week 16, while Q4W dosing effectively maintained disease control in responders. The incidence of conjunctivitis was similar during initial Q2W treatment and among patients continuing Q2W dosing, but was lower in those on Q4W dosing after Week 16. [Extracted from the article] |
| Database: |
Academic Search Index |